Trial Profile

A phase II trial of neoadjuvant imatinib for large gastric GIST in Japan and Korea

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary)
Indications Gastrointestinal stromal tumours
Focus Therapeutic Use

Most Recent Events

28 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network- Japan record.
18 Dec 2013 Primary endpoint is changed from progression free survival to complete resection rate as per University Hospital Medical Information Network- Japan record.
17 Dec 2013 Planned number of patients changed from 40 to 55 as reported by University Hospital Medical Information Network- Japan record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com